|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSPAN13 |
Gene summary for TSPAN13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSPAN13 | Gene ID | 27075 |
| Gene name | tetraspanin 13 | |
| Gene Alias | NET-6 | |
| Cytomap | 7p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O95857 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27075 | TSPAN13 | P80T-E | Human | Esophagus | ESCC | 9.50e-13 | 3.61e-01 | 0.155 |
| 27075 | TSPAN13 | P82T-E | Human | Esophagus | ESCC | 2.11e-27 | 2.37e+00 | 0.1072 |
| 27075 | TSPAN13 | P83T-E | Human | Esophagus | ESCC | 2.78e-24 | 9.70e-01 | 0.1738 |
| 27075 | TSPAN13 | P84T-E | Human | Esophagus | ESCC | 1.59e-09 | 1.11e+00 | 0.0933 |
| 27075 | TSPAN13 | P89T-E | Human | Esophagus | ESCC | 2.22e-06 | 9.68e-02 | 0.1752 |
| 27075 | TSPAN13 | P91T-E | Human | Esophagus | ESCC | 1.79e-11 | 1.71e+00 | 0.1828 |
| 27075 | TSPAN13 | P94T-E | Human | Esophagus | ESCC | 1.37e-02 | 1.68e+00 | 0.0879 |
| 27075 | TSPAN13 | P107T-E | Human | Esophagus | ESCC | 1.19e-16 | 7.64e-01 | 0.171 |
| 27075 | TSPAN13 | P126T-E | Human | Esophagus | ESCC | 1.56e-05 | 1.55e+00 | 0.1125 |
| 27075 | TSPAN13 | P127T-E | Human | Esophagus | ESCC | 2.48e-24 | 7.08e-01 | 0.0826 |
| 27075 | TSPAN13 | P128T-E | Human | Esophagus | ESCC | 7.44e-62 | 3.04e+00 | 0.1241 |
| 27075 | TSPAN13 | P130T-E | Human | Esophagus | ESCC | 6.81e-86 | 2.63e+00 | 0.1676 |
| 27075 | TSPAN13 | C04 | Human | Oral cavity | OSCC | 3.38e-08 | 6.65e-01 | 0.2633 |
| 27075 | TSPAN13 | C21 | Human | Oral cavity | OSCC | 7.00e-33 | 1.26e+00 | 0.2678 |
| 27075 | TSPAN13 | C30 | Human | Oral cavity | OSCC | 4.92e-42 | 2.11e+00 | 0.3055 |
| 27075 | TSPAN13 | C43 | Human | Oral cavity | OSCC | 1.04e-12 | 4.46e-01 | 0.1704 |
| 27075 | TSPAN13 | C46 | Human | Oral cavity | OSCC | 2.10e-51 | 1.18e+00 | 0.1673 |
| 27075 | TSPAN13 | C51 | Human | Oral cavity | OSCC | 4.91e-05 | 4.71e-01 | 0.2674 |
| 27075 | TSPAN13 | C57 | Human | Oral cavity | OSCC | 6.25e-17 | 5.60e-01 | 0.1679 |
| 27075 | TSPAN13 | C08 | Human | Oral cavity | OSCC | 1.53e-78 | 1.77e+00 | 0.1919 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00109596 | Breast | Precancer | regulation of metal ion transport | 37/1080 | 406/18723 | 4.07e-03 | 3.22e-02 | 37 |
| GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
| GO:0051924 | Breast | IDC | regulation of calcium ion transport | 32/1434 | 255/18723 | 3.94e-03 | 3.22e-02 | 32 |
| GO:001095921 | Breast | DCIS | regulation of metal ion transport | 50/1390 | 406/18723 | 2.86e-04 | 4.22e-03 | 50 |
| GO:0010959 | Colorectum | FAP | regulation of metal ion transport | 83/2622 | 406/18723 | 2.06e-04 | 2.96e-03 | 83 |
| GO:1904062 | Colorectum | FAP | regulation of cation transmembrane transport | 69/2622 | 357/18723 | 3.06e-03 | 2.30e-02 | 69 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSPAN13 | SNV | Missense_Mutation | c.270T>G | p.Phe90Leu | p.F90L | O95857 | protein_coding | tolerated(0.07) | benign(0.028) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TSPAN13 | SNV | Missense_Mutation | c.457N>T | p.Pro153Ser | p.P153S | O95857 | protein_coding | tolerated(0.26) | benign(0.175) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TSPAN13 | SNV | Missense_Mutation | c.356G>A | p.Arg119Gln | p.R119Q | O95857 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-QL-A97D-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSPAN13 | SNV | Missense_Mutation | rs763710458 | c.283N>A | p.Ala95Thr | p.A95T | O95857 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TSPAN13 | SNV | Missense_Mutation | novel | c.119T>G | p.Ile40Ser | p.I40S | O95857 | protein_coding | deleterious(0) | benign(0.398) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSPAN13 | SNV | Missense_Mutation | rs568219547 | c.244C>A | p.Leu82Met | p.L82M | O95857 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSPAN13 | SNV | Missense_Mutation | c.43N>A | p.Ala15Thr | p.A15T | O95857 | protein_coding | deleterious(0.05) | benign(0.066) | TCGA-AP-A0LE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TSPAN13 | SNV | Missense_Mutation | novel | c.112G>T | p.Gly38Trp | p.G38W | O95857 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-55-6979-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| TSPAN13 | SNV | Missense_Mutation | novel | c.200N>T | p.Ala67Val | p.A67V | O95857 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-KU-A66T-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| TSPAN13 | SNV | Missense_Mutation | novel | c.188N>A | p.Gly63Asp | p.G63D | O95857 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-UF-A7JF-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |